Kamada Ltd. (KMDA), a global biopharmaceutical company specializing in plasma-derived therapies, continues to demonstrate steady operational strength and clinical progress. With recent approvals, solid financials, and advancing programs, the company continues to build momentum. Notably, its pivotal Phase 3 InnovAATe trial for inhaled Alpha-1 Antitrypsin (AAT) therapy is undergoing an interim futility analysis this quarter, highlighting Kamada's dual focus on plasma capacity expansion and late-stage innovation.
Company Overview
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com